<DOC>
	<DOC>NCT00843661</DOC>
	<brief_summary>- The aim of the study is to compare the effects of coadministration of ezetimibe 10 mg/die + fenofibrate 200 mg/die versus pravastatin 40 mg/die monotherapy in HIV-infected patients treated with protease inhibitors. - Single-centre, open, randomized, controlled, prospective pilot study. - 60 patients will be enrolled in order to reach the target of 50 patients evaluable at the end of the study. The patients will be randomly assigned to a 6-month treatment with ezetimibe+fenofibrate or with pravastatin.The visit will be every month.</brief_summary>
	<brief_title>Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>patients older than 18 years documented positive HIV antibodies test on stable therapy with PIs for at least 12 months LDLcholesterol &gt;130 mg/dl or triglycerides 200 500 mg/dl with nonHDL cholesterol &gt;160 mg/dl unresponsive to dietary measures and regular physical exercise of at history of dyslipidemia before antiretroviral therapy cardiovascular and cerebrovascular diseases Cushing's syndrome concurrent therapy with lipidlowering agents, oral anticoagulant, estrogens, thiazidic diuretics, betablockers hypothyroidism Type 1 diabetes mellitus renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>